ROUNDUP 2: EMA clears the way for two new Covid drugs
Medicines in tablet form (symbolic image). © pixabay.com/CC0
(Information on medication added)
AMSTERDAM (dpa-AFX) – The European Medicines Agency EMA has cleared the way for the approval of two new drugs against Covid-19. It is about the antibody therapy Ronapreve from the Swiss pharmaceutical company Roche
The EMA experts had checked and evaluated all the manufacturer’s data from studies on the effectiveness and possible side effects of the agents. After the positive recommendation, the EU Commission must make the final decision. But that is a matter of form. Previously, Remdesivir (trade name Veklury) was the only drug approved in the EU – but only for certain seriously ill corona patients.
Ronapreve consists of two antibodies (casirivimab and imdevimab). It is made by the US manufacturer Regeneron Pharmaceuticals (Regeneron Pharmaceuticals share)
The EMA experts refer to the results of a study. Accordingly, less than one percent of Covid patients had to be admitted to hospital after treatment with Ronapreve or even died. In contrast, this was 3.4 percent of the patients in the comparison group. A total of 1193 patients were involved in this study.
The Regkirona remedy is intended to treat adults who are at high risk of developing a severe disease, who have Covid-19 but do not yet need oxygen. According to the EMA, a study shows that three percent of the patients treated with it actually had to be admitted to clinics, were given oxygen or even died. In the patients who had not received the remedy, the very serious courses of the disease occurred more frequently, namely in about eleven percent. A total of 880 patients took part in this study.
The European Commissioner for Health, Stella Kyriakides, welcomed the decision. “Today we are taking a giant step towards our goal of approving up to five new therapeutics in the EU by the end of the year.” / Ab / DP / he
|Short-term position in Regeneron Pharmaceuticals|
|with moderate leverage|
HSBC Trinkaus & Burkhardt AG
Subscribe to more news about the knock-out (NASDAQOTH: VQ9F70) for free
ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that is recognizably posted by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.
Other users were also interested in this article: